-transparent.png){kind=logo}
Management of disseminated non-small-cell lung cancer has changed over the past 10 years. Newer agents, such as vinorelbine (Navelbine) and paclitaxel (Taxol), have been shown to modestly improve survival in patients with advanced disease when administered in conjunction with cisplatin (Platinol). Compared with older regimens consisting of cisplatin and a Vinca alkaloid or a podophyllotoxin, the newer regimens yield a 10- to 15-week improvement in median survival and an additional 10% to 15% in 1-year survival. Based on these results derived from randomized trials, it appears that metastatic non-small-cell lung cancer patients with good performance status should be treated with regimens containing either vinorelbine or paclitaxel in conjunction with cisplatin.
D H Johnson, and
A Y Chang, and
D S Ettinger, and
K M Kim, and
P Bonomi
January 1996,
Journal of the National Cancer Institute. Monographs,
D H Johnson, and
A Y Chang, and
D S Ettinger, and
K M Kim, and
P Bonomi
December 1983,
Cancer,
D H Johnson, and
A Y Chang, and
D S Ettinger, and
K M Kim, and
P Bonomi
January 1997,
Oncology,
D H Johnson, and
A Y Chang, and
D S Ettinger, and
K M Kim, and
P Bonomi
January 1988,
Progress in clinical and biological research,
D H Johnson, and
A Y Chang, and
D S Ettinger, and
K M Kim, and
P Bonomi
January 1991,
Leukemia research,
D H Johnson, and
A Y Chang, and
D S Ettinger, and
K M Kim, and
P Bonomi
November 1992,
Leukemia,
D H Johnson, and
A Y Chang, and
D S Ettinger, and
K M Kim, and
P Bonomi
November 1980,
Cancer,
D H Johnson, and
A Y Chang, and
D S Ettinger, and
K M Kim, and
P Bonomi
September 1977,
Cancer treatment reports,
D H Johnson, and
A Y Chang, and
D S Ettinger, and
K M Kim, and
P Bonomi
September 1984,
Cancer,
D H Johnson, and
A Y Chang, and
D S Ettinger, and
K M Kim, and
P Bonomi
October 1995,
Seminars in oncology,
